Clinical and biological significance of EZH2 expression in endometrial cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006;4(6):459–468.
   PubMedGoogle Scholar
• Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18(3):409–420. doi:10.1093/annonc/mdl417.
   PubMed Web of Science ®Google Scholar
• Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev. 2002;12(2):210–218. doi:10.1016/S0959-437X(02)00288-5.
   PubMed Web of Science ®Google Scholar
• Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12(4):1168–1174. doi:10.1158/1078-0432.CCR-05-1533.
   PubMed Web of Science ®Google Scholar
• Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005;16(2):349–353. doi:10.3892/ijmm.16.2.349.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–629. doi:10.1038/nature01075.
   PubMed Web of Science ®Google Scholar
• Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484–491. doi:10.1111/j.1349-7006.2006.00203.x.
   PubMed Web of Science ®Google Scholar
• Choi H, Chang JW, Jung YK. Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ. 2010;18(3):405–414. doi:10.1038/cdd.2010.113.
   PubMed Web of Science ®Google Scholar
• Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, Kim YM, Nam JH. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 2011;29(1):21–28. doi:10.3109/07357907.2010.535056.
   PubMed Web of Science ®Google Scholar
• Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, et al. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 2013;128(2):344–348. doi:10.1016/j.ygyno.2012.07.128
   PubMed Web of Science ®Google Scholar
• Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185–197. doi:10.1016/j.ccr.2010.06.016
   PubMed Web of Science ®Google Scholar
• Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci USA. 2002;99(18):11599–11604. doi:10.1073/pnas.182384499.
   PubMed Web of Science ®Google Scholar
• Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem. 2003;278(27):25179–25190. doi:10.1074/jbc.M302706200.
   PubMed Web of Science ®Google Scholar
• Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005;38(12):1543–1552. doi:10.1016/j.freeradbiomed.2005.02.026.
   PubMed Web of Science ®Google Scholar
• Chen JW, Dodia C, Feinstein SI, Jain MK, Fisher AB. 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J Biol Chem. 2000;275(37):28421–28427. doi:10.1074/jbc.M005073200.
   PubMed Web of Science ®Google Scholar
• Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics. 2006;6(11):3352–3368. doi:10.1002/pmic.200500617
   PubMed Web of Science ®Google Scholar
• Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene. 2009;28(40):3551–3562. doi:10.1038/onc.2009.210.
   PubMed Web of Science ®Google Scholar
• Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011;104(8):1278–1287. doi:10.1038/bjc.2011.84.
   PubMed Web of Science ®Google Scholar
• Kang SH, Cho J, Jeong H, Kwon SY. High RNA-binding motif protein 3 expression is associated with improved clinical outcomes in invasive breast cancer. J Breast Cancer. 2018;21(3):288–296. doi:10.4048/jbc.2018.21.e34.
   PubMed Web of Science ®Google Scholar
• Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, et al. Biologic effects of platelet-derived growth factor receptor alpha blockade in uterine cancer. Clin Cancer Res. 2014;20(10):2740–2750. doi:10.1158/1078-0432.CCR-13-2507
   PubMed Web of Science ®Google Scholar
• Landen CN Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910–6918. doi:10.1158/0008-5472.CAN-05-0530.
   PubMed Web of Science ®Google Scholar
• Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res. 2009;15(11):3770–3780. doi:10.1158/1078-0432.CCR-08-2306
   PubMed Web of Science ®Google Scholar
• Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009;101(17):1193–1205. doi:10.1093/jnci/djp231
   PubMed Web of Science ®Google Scholar
• LC C, ME C, NJ W. Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc. 2016;2016(8). doi:10.1101/pdb.prot087171.
   Google Scholar
• Peng H, Wen J, Li H, Chang J, Zhou X. Drug inhibition profile prediction for NFkappaB pathway in multiple myeloma. PLoS One. 2011;6(3):e14750. doi:10.1371/journal.pone.0014750.
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009;124(5):1045–1053. doi:10.1002/ijc.24028.
   PubMed Web of Science ®Google Scholar
• Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010;16(15):3910–3922. doi:10.1158/1078-0432.CCR-10-0005.
   PubMed Web of Science ®Google Scholar
• Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009;8(11):1027–1034. doi:10.4161/cbt.8.11.8523
   PubMed Web of Science ®Google Scholar
• Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863–14868. doi:10.1073/pnas.95.25.14863.
   PubMed Web of Science ®Google Scholar